Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema

PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Yun, Steel, David H. W., Habib, Maged S., Stubbing-Moore, Alex, Bajwa, Dalvir, Avery, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Retinal Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364245/
https://www.ncbi.nlm.nih.gov/pubmed/27957600
http://dx.doi.org/10.1007/s00417-016-3562-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364245/
https://www.ncbi.nlm.nih.gov/pubmed/27957600
http://dx.doi.org/10.1007/s00417-016-3562-0

Ejemplares similares